Governance

Effective and transparent Corporate Governance fosters the confidence of our stakeholders in the management and supervision of the company. Our commitment to good corporate governance promotes interests of our shareholders, strengthens the Supervisory Board, management accountability and trust of our client in Flash Therapeutics. Our business practices foster our strong innovative and collaborative culture, which is committed to ethical behaviour and strong values as of collective spirit, excellence and responsibility

About us dyptiques

Supervisory Board Members

Pascale Bouillé Ph.D - CEO of Flash Therapeutics

Initially involved in fundamental research in retrovirology, Pascale Bouillé has worked in a number of government and biotechnology research laboratories before creating Vectalys in 2005. From her early days as a PhD student for the Gustave Roussy Institute (Professor Claude Paoletti) and postdoctoral researcher for the Pasteur Institute (Professor Luc Montagnier), she built up over 15 years' experience in R&D projects in the fields of drug discovery and virology. Pascale Bouillé then participated in various programs, first, by conducting gene therapy trials for the Genethon laboratories with Dr Olivier Danos, then followed by the successful transition of viral vector tools from a technology-based to a commercially oriented product with Vectalys. Pascale was also the CEO of FlashCell. At the head of all the Flash Therapeutics’ team as the CEO of the Company, she provides a strong scientific background and a high level of expertise to scientists, project leaders and all the clients of Flash Therapeutics worldwide.

Luc Aguilar - Scientific Senior Advisor

Luc AGUILAR gathers 20 years of experience in the biotech, pharmaceutical and the cosmetic Industry. He joined L’Oreal seven years ago to build the biotechnology Department in Advance Research. He is now leading Advanced Research activities from Scientific Knowledge to Clinical Performance for skin and hair categories. From 2005 to 2011, he was at Pierre Fabre’s Group, a mid-size pharmaceutical company, as Vice-President Scientific Affairs. During this period, he set up and led an innovation structure dedicated to clinical proof of concept studies. Prior to that, he managed operations in Biotech and start-up companies in genomics for corporate clients from 1995 to 2001. He earned a MS in Biotechnology from I.N.S.A.Toulouse, France and a PhD experience at Pierre et Marie Curie University.

Jean-Pierre Arnaud - President of Giralda Holding

Jean Pierre Arnaud received his D.V.M. from the National Veterinary School of Maison-Alfort, France, then got a certificate in Nutrition for food-production animals (CSAAD) and a specialization in poultry production from the National School of Agronomics of Paris-Grignon, he also got a certificate in Statistics from University of Paris VI. He co-founded Avogadro in May 1998 after having worked ten years at Rhone Merieux/Merial starting as clinician and finally as Manager of the Drug Safety Department. Prior he was, for seven years, veterinary technical advisor in animal food at a French company after practicing for five years mainly as a bovine and sheep medicine veterinarian. He was the General Manager of Amatsigroup resulting of the merger of Avogadro and Amatsi in 2013 and of Avogadro LS, a company specialized in in-life studies until 2018. He continues to provide his expertise and advices to his clientele. Jean-Pierre Arnaud is a shareholder of Flash Therapeutics.

Thierry Bardon - Investment director at Fa dièse

Veterinary surgeon, Thierry Bardon worked in medicine R&D, health (Rhône Poulenc Santé), Animal healthcare (CEVA Santé Animale). He is involved in numerous startups and acquired financial skills when he joined Fa Dièse in 2007 to provide young entrepreneurs all his experience in the healthcare industry.

Claudia Daugan - Investment director at Galia Gestion

Graduate of ESC Reims (RMS) and holder of DESCF, Claudia DAUGAN began her career in 1997 at KPMG Audit in Paris where she carries out statutory auditing and consulting assignments for a banking clientele. In 2000, she joined Calyon's Equity Capital Market team, which is responsible for structuring and executing the issuance of securities of major groups (listed equities and convertible bonds). From 2004 to 2009, after joining the Bordeaux region, she continued her career at Crédit Lyonnais as Deputy of Corporate Finance. She accompanies SME managers and buyers of companies in their "equity financing". Since 2009, Claudia DAUGAN has strengthened the team of investors of GALIA Gestion as Senior Business Manager and then Director of Investments. She currently follows a portfolio of a dozen companies in diversified business sectors (ICT, Services, Medical).

Franck Lescure - General partner Bioseeds IV Auriga Partners

Franck Lescure is in charge of Life Sciences investments at AURIGA Partners. He manages the Fund AURIGA IV Bioseeds specialized in Infectiology and Microbiology and is directly involved in commitments of AURIGA Partners Funds in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab’entech, Flashcell, Pherecydes, Median Technologies (Alternext: ALMDT), Nosopharm and Pylote. Before Auriga Partners, Franck has been part as a scientist of the five initial years of Genset, one of the first French biotech startups, he has spent several years in the Air Liquide group and has been in charge of several investments as member of the Venture Capital team of Crédit Lyonnais Private Equity which became Omnes Capital. Franck is an alumnus of the Ecole Normale Supérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.

Paul Steuperaert - Business Angel

Paul

A Strategic Advisory Board with accomplished senior experts

A Board of accomplished senior experts in pharmaceutical R&D, Health & Life Sciences, Gene Therapy and Branding to give strategic, innovative & accurate advices for the development of the company, especially for business development, licensing strategy, global brand strategy, regulatory affairs and therapeutic & (pre) clinical developments. Members of this Flash Therapeutics Strategic Advisory Board have a strong background in pharmacology and gene therapy, including product development, and clinical trials approval.

Pascale Bouillé Ph.D - CEO of Flash Therapeutics

Initially involved in fundamental research in retrovirology, Pascale Bouillé has worked in a number of government and biotechnology research laboratories before creating Vectalys in 2005. From her early days as a PhD student for the Gustave Roussy Institute (Professor Claude Paoletti) and postdoctoral researcher for the Pasteur Institute (Professor Luc Montagnier), she built up over 15 years' experience in R&D projects in the fields of drug discovery and virology. Pascale Bouillé then participated in various programs, first, by conducting gene therapy trials for the Genethon laboratories with Dr Olivier Danos, then followed by the successful transition of viral vector tools from a technology-based to a commercially oriented product with Vectalys. Pascale was also the CEO of FlashCell. At the head of all the Flash Therapeutics’ team as the CEO of the Company, she provides a strong scientific background and a high level of expertise to scientists, project leaders and all the clients of Flash Therapeutics worldwide.

Nicolas Ferry Ph.D - Regulatory affairs

Graduated from Paris University where he received a Ph D in 1985 and a M.D. in 1990, Nicolas served as a scientist at the French National Institute for Health Science (INSERM) for more than 25 years. He focused his interest in liver research (creation of its own INSERM lab in Nantes in 2009) and contributed to clinical trials of cell based therapy for liver diseases. Following a role of gene therapy expert for the French regulatory authority, he joined the agency as head of the department of vaccines, blood derived products and advanced therapies. Nicolas is now senior advisor at the cell therapy department of Saint Louis Hospital in Paris and works as a private consultant in the field of ATMPs. Nicolas Ferry co-authored more than 100 scientific publications.

Jean-Marc Herbert Ph.D - Therapeutic & clinical developments

Jean-Marc Herbert received an Engineer Degree in Biochemistry and a Ph.D. in cellular and molecular biology from the University of Clermont-Ferrand, France. He has more than 30 years of industrial experience in pharmaceutical R&D. During 10 years, he worked as International Director of the Cardiovascular/thrombosis Research Department for Sanofi R&D. He was Senior VP, in charge of Discovery at Sanofi-Aventis Research, the interim Head of the Anti-infectious Unit and Head of the Early-to-Candidate (E2C) department at Sanofi. He played key roles in the discovery of more than 20 compounds including Plavix® and Arixtra®, and actively contributed to the discovery and development of more than 70 other. He has authored more than 400 papers and is listed as an inventor in more than 50 patents in various fields, including thrombosis, vascular biology, inflammation, cardiology and cancer. Since January 2016, J-M Herbert is the President of Arkely-Consulting, a translational research consulting firm focused on helping biomedical science-based organizations to solve complex challenges associated with modern drug discovery and development. Since January 2017, he acts as a Venture partner for Go Capital, one of the biggest investment funds in France.

Jean-Christophe Huertas - Global Brand Strategy & Marketing Communication

Jean-Christophe Huertas has more than 25 years of experience in Brand & Communications within worldwide companies in global and complex organizations. After 8 years (1991-1999) in media relations at Airbus, Alcatel and Rhône Poulenc (Rhodia), he was given global corporate & public affairs communications responsibilities: Rhodia Senior VP Communications & Executive Committee member (1999-2005) ; Executive VP Communications & Public Affairs of Nestlé France & Executive Committee member; Managing Director, Brand & Communications & Executive Committee member of  Newedge (50/50 JV between Société Générale and Crédit Agricole), a leading Company in the world of multi-asset brokerage (2008-2012). Then, he joined in 2013 the international FTI Consulting Strategic Communications practice, as Vice-President leading the corporate communications and media Department. Since 2014, he is the CEO of H2D Advisory, a consulting & advisory firm specialized in Strategy & Communications. JC Huertas obtained a degree in law and is a graduate of the Institut d’Etudes Politiques. He as a post-graduate diploma (DESS) in Defense & International Relations of the University Paris 2 Panthéon-Assas.

Alain Sainsot - Industrial Development

Alain Sainsot holds a university degree in Pharmacy and a MBA. He has over 30  years of experience in Pharmaceutical Development and Manufacturing. He was until February 2018 the President of AMATSIGROUP, a CDMO specialized in the subcontracting of formulation and analytical development, manufacturing, distribution of clinical lots and the quality control (small & large molecules). In 2006, he has founded DBI, a CMO specialized in outsourcing of highly potent injectable sterile drugs (anticancer drugs, vaccines, biotechnology products) for pilot batches, pre-clinical or clinical. During his career, Alain Sainsot hold executive positions in the pharmaceutical industry: Director of Industrial operations and logistics of the PIERRE FABRE Group, member of the Executive Committee ; industrial Director and Qualified Person of PIERRE FABRE MEDICAMENT and plant manager of AQUITAINE PHARM INTERNATIONAL (facility dedicated to sterile manufacturing, mainly involved into CMO Business) ; plant manager in agrofood industry area. Alain is also Board member of the Innovation and Development Agency (ADI) from the Regional Council of Aquitaine. Alain Sainsot is a shareholder of Flash Therapeutics.

Jean-Pierre Saintouil - Licensing & Business Development

With a training in Biochemistry and Business, Jean-Pierre Saintouil has a 35 years experience in the field of Health and Life Sciences. He has been successively responsible for International Sales and Director Marketing at Sanofi and Beckman, Director of Business Unit for Bio-Rad, Director of Technology transfer and Licensing at Pasteur Institute, Director of the Cancer-Bio-Santé Cluster and Director of the health Business Unit of Toulouse-Tech-Transfer.

Management Team

Based on the funder Pascale Bouillé’s fundamental skills in HIV virology and vectorology, the company’s scientific expertise has continuously increased within the 12 years of development of Vectalys. This core competence was gradually expanded thanks to Vectalys current multidisciplinary team and its skills in genetics, cellular biology and production processes. They are today dedicated to the development and the success of Flash Therapeutics

Pascale Bouillé Ph.D - CEO of Flash Therapeutics

Initially involved in fundamental research in retrovirology, Pascale Bouillé has worked in a number of government and biotechnology research laboratories before creating Vectalys in 2005. From her early days as a PhD student for the Gustave Roussy Institute (Professor Claude Paoletti) and postdoctoral researcher for the Pasteur Institute (Professor Luc Montagnier), she built up over 15 years' experience in R&D projects in the fields of drug discovery and virology. Pascale Bouillé then participated in various programs, first, by conducting gene therapy trials for the Genethon laboratories with Dr Olivier Danos, then followed by the successful transition of viral vector tools from a technology-based to a commercially oriented product with Vectalys. Pascale was also the CEO of FlashCell. At the head of all the Flash Therapeutics’ team as the CEO of the Company, she provides a strong scientific background and a high level of expertise to scientists, project leaders and all the clients of Flash Therapeutics worldwide.

Brigitte Mignotte-Darmon - Finance, CAO & HR

With more than 20 years' experience in the development of HR policies for international groups, Brigitte joined Vectalys in 2008. She has gained extensive knowledge from working in different R&D environments including a large American technology company and a leading CRO. Brigitte manages the administrative organization at Flash Therapeutics  directing and overseeing policy related to staff and ancillary services. She ensures the development and progress of the company’s organization and has set up a genuine HR policy to support company growth and to prepare Flash Therapeutics for the developments of tomorrow.

Yohann Moal - Marketing

Yohann obtained his master's degree in biotechnology and bioproduction engineering from the ENSTBB of Bordeaux. He then moved to the UK, working as a downstream process development scientist at Oxford BioMedica Ltd, where he acquired hands-on experience in the development of a phase III clinical trial process for lentiviral vectors. Yohann joined Vectalys in 2009 as project manager for downstream process development in the field of purification, and in an R&D collaborative project to develop new non-integrating viral particles. Always attentive to customers' needs, Yohann quickly became in charge of customer technical support in 2011 and his functions included helping customers with the development of their vector application projects. In parallel, he has acquired strong skills in marketing and webmarketing following a dual training in marketing and sales techniques from Toulouse Business School. Yohann is now marketing manager of Flash Therapeutics. 

Adriana Georges - Business Development

Adriana joined Vectalys to develop its international business. In addition to her Master’s degree in biochemical engineering from the National Institute of Applied Sciences (INSA-T, France), she obtained a master’s degree in Innovation Management at the University Of Toulouse Graduate School Of Management in 2004 then at Harvard University (Cambridge, MA – USA) in 2006. Since 2004, Adriana coordinated multidisciplinary teams (R&D, sales…) to develop, in Europe, North America and in Asia, many high value-added technologies and product concepts for innovative companies in France and in the US. These successful experiences, combined with her scientific background, give her all the qualities to expand  Flash Therapeutics  products and services worldwide.

Sandy Darrigan - Intellectual Property

After an initial qualification in cell biology and biotechnologies, Sandy specialized in intellectual property with a master’s degree of Intellectual Property and New technologies (Paul Sabatier University, Toulouse-France) and a master’s degree Patents and Trademarks of the Center for International Intellectual Property Studies (CEIPI, Strasbourg-France). After a first experience in a biotech company, Sandy joined Vectalys in 2012 to developp its patents portfolio. With these double skills, she is now in charge of Flash Therapeutics intellectual property strategy, including patents and in/out licences management. Her functions include the management of contractual aspects with Flash Therapeutics’ customers and partners.

Lucille Lamouroux Ph.D - Gene Engineering

Lucille joined Vectalys in 2011. She began her career as a PhD student and scientific engineer in 2002 doing academic research in the field of life sciences. Since then she has successfully led the introduction of new technologies in biochemistry, genomics and molecular biology, including high-throughput experiments and the development of heterologous expression systems. Her in-depth knowledge of the processes involved in the development of expression systems significantly helps to understand our customers’ needs. Lucille helps customers to identify and implement relevant tools that will bring value to their research.

Régis Gayon - Cell Engineering

After an MSc degree in cellular and molecular biology from the University of Montpellier, France, Régis began his career in an academic laboratory (INSERM, Paris) where he initiated a transcriptomics project to help understand Type I diabetes. Régis then spent 5 years as an R&D associate scientist at Endocube (Toulouse, France) where he was involved in a cellular genomics project, acquiring expertise in the purification and culture of primary cells in the field of vascular biology. Régis joined Vectalys in 2005 as head of the Cell Models team. Since September 2012, he is also in charge production development, purification and concentration of viral vectors, bringing his expertise in cellular biology to ensure performance and reliability of viral vectors produced at Vectalys. As head of the Vectors and Cell Models Teams, and strong of his experience of over 12 years in cellular and molecular biology, he oversees the viral vector production process and its enhancements, as well as manages the generation of new cellular models, from design to delivery, for use in the fields of bioproduction, gene target validation and drug discovery.

Christine Duthoit Ph.D - In Vivo Engineering

Christine obtained her PhD in 2000 and then worked for eight years in the United States and France, where she successfully led various projects examining immune responses in different animal models for autoimmune diseases. She gained experience in in vivo experimentation, animal care, biochemistry and cell biology after spending several years in academic research before becoming the head of the Animal Models department at Vectalys in 2008. Her knowledge is now a key element for the development and testing of new animal models for Vectalys’ customers.

Carole Fernandez - Quality

After earning a master’s degree in Biochemical Engineering from the National Institute of Applied Sciences (INSA, France), Carole specialized in the Quality field. In 2002, she earned a second master’s degree from the Institute of Food Industry (ISAA-P, France). For 10 years, she worked on several Quality Systems certifications: ISO 9001, ISO 22 000 – HACCP, GMP, ECOCERT and ECOCERT Greenlife (COSMEBIO) in probiotics, food supplements and herbal drugs industries. Carole joined Vectalys in 2012. Today, she supervises the Quality department (Quality Assurance and Quality Control). Part of her mission is to ensure the implementation of Good Laboratory Practices and Good Manufacturing practices in the production process. She is also in charge of supporting Flash Therapeutics in its international development and managing our Assurance Quality system for continuous improvement.